Summary:
Hyderabad, Sept 21 (PTI) Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said on Tuesday here.
Speaking to reporters, he said Covaxin production would touch 55 million doses in October as against 35 million in September.
He also said the Phase 2 trials of the firm"s intranasal vaccine against COVID-19 is expected to be over by next month.
“Paediatric Covaxin just completed phase 2/3 trials.
The data analysis is going on.
We will be submitting the data ( to the regulator) by next week.